Abstract
Methamphetamine (METH) is a highly addictive psychostimulant, and cessation of use is associated with reduced monoamine signalling, and increased anxiety/depressive states. Neurons expressing the neuropeptide, relaxin-3 (RLN3), and its cognate receptor, RXFP3, constitute a putative ‘ascending arousal system’, which shares neuroanatomical and functional similarities with serotonin (5-HT)/dorsal raphe and noradrenaline (NA)/locus coeruleus monoamine systems. In light of possible synergistic roles of RLN3 and 5-HT/NA, endogenous RLN3/RXFP3 signalling may compensate for the temporary reduction in monoamine signalling associated with chronic METH withdrawal, which could alter the profile of ‘behavioural despair’, bodyweight reductions, and increases in anhedonia and anxiety-like behaviours observed following chronic METH administration. In studies to test this theory, Rln3 and Rxfp3 knockout (KO) mice and their wildtype (WT) littermates were injected once daily with saline or escalating doses of METH (2 mg/kg, i.p. on day 1, 4 mg/kg, i.p. on day 2 and 6 mg/kg, i.p. on day 3–10). WT and Rln3 and Rxfp3 KO mice displayed an equivalent sensitivity to behavioural despair (Porsolt swim) during the 2-day METH withdrawal and similar bodyweight reductions on day 3 of METH treatment. Furthermore, during a 3-week period after the cessation of chronic METH exposure, Rln3 KO, Rxfp3 KO and corresponding WT mice displayed similar behavioural responses in paradigms that measured anxiety (light/dark box, elevated plus maze), anhedonia (saccharin preference), and social interaction. These findings indicate that a whole-of-life deficiency in endogenous RLN3/RXFP3 signalling does not markedly alter behavioural sensitivity to chronic METH treatment or withdrawal, but leave open the possibility of a more significant interaction with global or localised manipulations of this peptide system in the adult brain.
Similar content being viewed by others
References
Barr AM, Markou A, Phillips AG (2002) A ‘crash’ course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 23:475–482
Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085–1099
Bamford NS, Zhang H, Joyce JA, Scarlis CA, Hanan W, Wu NP, Andre VM, Cohen R, Cepeda C, Levine MS, Harleton E, Sulzer D (2008) Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron 58:89–103
Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T (2006) The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31:301–313
Yamamoto BK, Moszczynska A, Gudelsky GA (2010) Amphetamine toxicities: classical and emerging mechanisms. Ann New York Acad Sci 1187:101–121
Kita T, Wagner GC, Nakashima T (2003) Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 92:178–195
Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM (2013) Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 129:167–179
Reichel CM, Ramsey LA, Schwendt M, McGinty JF, See RE (2012) Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology 62:1119–1126
Armstrong BD, Noguchi KK (2004) The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in vitro autoradiographic study in rats. Neurotoxicology 25:905–914
Cryan JF, Hoyer D, Markou A (2003) Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54:49–58
Kokkinidis L, Zacharko RM, Anisman H (1986) Amphetamine withdrawal: a behavioral evaluation. Life Sci 38:1617–1623
Kitanaka N, Kitanaka J, Tatsuta T, Tanaka K, Watabe K, Nishiyama N, Morita Y, Takemura M (2010) Withdrawal from fixed-dose injection of methamphetamine decreases cerebral levels of 3-methoxy-4-hydroxyphenylglycol and induces the expression of anxiety-related behavior in mice. Neurochem Res 35:749–760
Tanaka M, Yoshida M, Emoto H, Ishii H (2000) Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol 405:397–406
Ma S, Bonaventure P, Ferraro T, Shen PJ, Burazin TCD, Bathgate RAD, Liu C, Tregear GW, Sutton SW, Gundlach AL (2007) Relaxin-3 in GABA projection neurons of nucleus incertus suggests widespread influence on forebrain circuits via G-protein–coupled receptor-135 in the rat. Neuroscience 144:165–190
Smith CM, Shen PJ, Banerjee A, Bonaventure P, Ma S, Bathgate RAD, Sutton SW, Gundlach AL (2010) Distribution of relaxin-3 and RXFP3 within arousal, stress, affective and cognitive circuits of mouse brain. J Comp Neurol 518:4016–4045
Lesch KP, Waider J (2012) Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 76:175–191
Saper CB, Scammell TE, Lu J (2005) Hypothalamic regulation of sleep and circadian rhythms. Nature 437:1257–1263
Goto M, Swanson LW, Canteras NS (2001) Connections of the nucleus incertus. J Comp Neurol 438:86–122
Olucha-Bordonau FE, Teruel V, Barcia-Gonzalez J, Ruiz-Torner A, Valverde-Navarro AA, Martinez-Soriano F (2003) Cytoarchitecture and efferent projections of the nucleus incertus of the rat. J Comp Neurol 464:62–97
Ryan PJ, Ma S, Olucha-Bordonau FE, Gundlach AL (2011) Nucleus incertus—an emerging modulatory role in arousal, stress and memory. Neurosci Biobehav Rev 35:1326–1341
Ma S, Gundlach AL (2015) Ascending control of arousal and motivation: role of nucleus incertus and its peptide neuromodulators in behavioural responses to stress. J Neuroendocrinol. doi:10.1111/jne.12259
Smith CM, Walker AW, Hosken IT, Chua BE, Zhang C, Haidar M, Gundlach AL (2014) Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Front Pharmacol 5:46
Ryan PJ, Buchler E, Shabanpoor F, Hossain MA, Wade JD, Lawrence AJ, Gundlach AL (2013) Central relaxin-3 receptor (RXFP3) activation decreases anxiety—and depressive-like behaviours in the rat. Behav Brain Res 244:142–151
Watanabe Y, Miyamoto Y, Matsuda T, Tanaka M (2011) Relaxin-3/INSL7 regulates the stress-response system in the rat hypothalamus. J Mol Neurosci 43:169–174
Banerjee A, Shen PJ, Ma S, Bathgate RAD, Gundlach AL (2010) Swim stress excitation of nucleus incertus and rapid induction of relaxin-3 expression via CRF1 activation. Neuropharmacology 58:145–155
Tanaka M, Iijima N, Miyamoto Y, Fukusumi S, Itoh Y, Ozawa H, Ibata Y (2005) Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. Eur J Neurosci 21:1659–1670
Bathgate RAD, Lin F, Hanson NF, Otvos L Jr, Guidolin A, Giannakis C, Bastiras S, Layfield SL, Ferraro T, Ma S, Zhao C, Gundlach AL, Samuel CS, Tregear GW, Wade JD (2006) Relaxin-3: improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo. Biochemistry 45:1043–1053
Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C, Farmer N, Jornvall H, Sillard R, Lovenberg TW (2003) Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein–coupled receptor GPCR135. J Biol Chem 278:50754–50764
Chen J, Kuei C, Sutton SW, Bonaventure P, Nepomuceno D, Eriste E, Sillard R, Lovenberg TW, Liu C (2005) Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species. J Pharmacol Exp Ther 312:83–95
Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, Yanagisawa M, Sakurai T (2003) Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38:701–713
Tsujino N, Sakurai T (2013) Role of orexin in modulating arousal, feeding and motivation. Front Behav Neurosci 7:28
Smith CM, Lawrence AJ, Sutton SW, Gundlach AL (2009) Behavioral phenotyping of mixed background (129S5:B6) relaxin-3 knockout mice. Ann NY Acad Sci 1160:236–241
Hosken IT, Sutton SW, Smith CM, Gundlach AL (2014) Relaxin-3 receptor (Rxfp3) gene knockout mice display reduced running wheel activity: implications for role of relaxin-3/RXFP3 signalling in sustained arousal. Behav Brain Res 278:167–175
Kobeissy FH, Jeung JA, Warren MW, Geier JE, Gold MS (2008) Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats. Addict Biol 13:15–25
Smith CM, Chua BE, Zhang C, Walker AW, Haidar M, Hawkes D, Shabanpoor F, Hossain MA, Wade JD, Rosengren KJ, Gundlach AL (2014) Central injection of relaxin-3 receptor (RXFP3) antagonist peptides reduces motivated food seeking and consumption in C57BL/6 J mice. Behav Brain Res 268:117–126
Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza II R, Traynor JR, Woods JH (2008) A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151:533–543
Miyamoto Y, Watanabe Y, Tanaka M (2008) Developmental expression and serotonergic regulation of relaxin 3/INSL7 in the nucleus incertus of rat brain. Regul Pept 145:54–59
Vuong SM, Oliver HA, Scholl JL, Oliver KM, Forster GL (2010) Increased anxiety-like behavior of rats during amphetamine withdrawal is reversed by CRF2 receptor antagonism. Behav Brain Res 208:278–281
Reinbold ED, Scholl JL, Oliver KM, Watt MJ, Forster GL (2014) Central CRF receptor antagonism reduces anxiety states during amphetamine withdrawal. Neurosci Res 89:37–43
Ma S, Blasiak A, Olucha-Bordonau FE, Verberne AJ, Gundlach AL (2013) Heterogeneous responses of nucleus incertus neurons to corticotrophin-releasing factor and coherent activity with hippocampal theta rhythm in the rat. J Physiol (Lond) 591:3981–4001
Walker AW, Smith CM, Chua BE, Krstew EV, Zhang C, Gundlach AL, Lawrence AJ (2015) Relaxin-3 receptor (RXFP3) signalling mediates stress-related alcohol preference in mice. PLoS ONE 10:e0122504
Smith CM, Hosken IT, Sutton SW, Lawrence AJ, Gundlach AL (2012) Relaxin-3 null mutation mice display a circadian hypoactivity phenotype. Genes Brain Behav 11:94–104
Segal DS, Kuczenski R (1997) An escalating dose “binge” model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17:2551–2566
Piechota M, Korostynski M, Sikora M, Golda S, Dzbek J, Przewlocki R (2012) Common transcriptional effects in the mouse striatum following chronic treatment with heroin and methamphetamine. Genes Brain Behav 11:404–414
Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379–391
Ma S, Shen PJ, Sang Q, Lanciego JL, Gundlach AL (2009) Distribution of relaxin-3 mRNA and immunoreactivity and RXFP3-binding sites in the brain of the macaque, Macaca fascicularis. Ann NY Acad Sci 1160:256–258
Olucha-Bordonau FE, Otero-Garcia M, Sanchez-Perez AM, Nunez A, Ma S, Gundlach AL (2012) Distribution and targets of the relaxin-3 innervation of the septal area in the rat. J Comp Neurol 520:1903–1939
Blasiak A, Blasiak T, Lewandowski MH, Hossain MA, Wade JD, Gundlach AL (2013) Relaxin-3 innervation of the intergeniculate leaflet of the rat thalamus—neuronal tract-tracing and in vitro electrophysiological studies. Eur J Neurosci 37:1284–1294
Acknowledgments
This research was supported by National Health and Medical Research Council of Australia Project Grants 1005988 and 1024885 (ALG), grants from the Pratt and Besen Family Foundation (ALG), a Brain & Behavior Research Foundation (USA) NARSAD Independent Investigator Award (ALG), and the Victorian Government Operational Infrastructure Support Programme. MH is the recipient of a postgraduate scholarship from the Alzheimer’s Australia Dementia Research Foundation. The authors thank Timothy Lovenberg and Steve Sutton (Janssen Companies of Johnson & Johnson, San Diego, CA, USA) for commissioning and providing the original Rln3 and Rxfp3 knockout mice.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Special Issue: In Honor of Dr. Philip Beart.
Craig M. Smith and Andrew L. Gundlach jointly supervised this research.
Rights and permissions
About this article
Cite this article
Haidar, M., Lam, M., Chua, B.E. et al. Sensitivity to Chronic Methamphetamine Administration and Withdrawal in Mice with Relaxin-3/RXFP3 Deficiency. Neurochem Res 41, 481–491 (2016). https://doi.org/10.1007/s11064-015-1621-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-015-1621-2